One of the Four Little Dragons of domestically produced dexterous hands has received nearly 100 million yuan in financing

Recently, Shanghai Aoyi Information Technology Co., Ltd. (hereinafter referred to as Aoyi Technology) announced the completion of a B++round of nearly 100 million yuan financing. This round of financing is jointly invested by Infineon Capital, Zhejiang Development Asset Management Co., Ltd., a subsidiary of Zhejiang State owned Capital Operation Co., Ltd., and Womeda Capital, with Shengke Capital serving as the long-term financial advisor. This is a new round of financing that was quickly delivered within three months after Aoyi Technology completed its B+round of financing at the end of 2024, fully demonstrating Aoyi Technology's strong development momentum and high market recognition.

This round of financing will inject strong momentum into Aoyi Technology, helping the company achieve leapfrog development in multiple key areas. The funds will be mainly used to accelerate the continuous research and development breakthroughs in the field of dexterous hand technology, promote the launch process of the new generation of dexterous hand products, and accelerate the launch progress of finger joint exoskeleton robots. At the same time, establish an internationally leading standardized production system, optimize production processes, and achieve 100% annual capacity growth. In addition, Aoyi Technology will further promote its global market layout and provide better and more efficient solutions for global customers.

In 2015, Aoyi Technology was officially established in Zhangjiang High tech Park, Shanghai. As one of the few innovative enterprises in China that simultaneously master the two core technologies of brain computer interface and robotics, the company has always focused on the cross integration of neuroscience and robotics technology, and successfully built an independent research and development platform of "neural interface robot AI algorithm". After nearly a decade of technological accumulation, Aoyi Technology has developed multiple innovative products that combine technological leadership and commercial feasibility, and their product performance and cost-effectiveness have been widely recognized in the global market.

In the cutting-edge field of embodied robots, Aoyi Technology's first dexterous hand product has currently served multiple customers of body robots and has received widespread praise. On the one hand, as one of the most important upstream solutions for ontology robots, dexterous hands have always been highly anticipated by the industry. On the other hand, as a representative product of precision intelligent manufacturing, dexterous hand products have high technical barriers, complex process difficulties, and strict system requirements. Therefore, in the dexterous hand industry, there has always been an impossible triangle, which is difficult to balance the requirements of "cost+system parameters+system stability".

Aoyi Technology is the earliest team in China to focus on the research of hand robots. Since 2017, it has completed dozens of iterations and successfully promoted the landing of hand robots in various scenarios, such as the intelligent bionic hand provided for amputees with integrated neural interfaces (electromyography), multiple dexterous hand products for embodied intelligent customers, and finger joint exoskeleton robot products for people with hand dysfunction.

As one of the few manufacturers on the market with experience in mass production and the ability to deliver in bulk, Aoyi has achieved the impossible triangle balance by building multiple scene SKUs, and has become an important player in the first tier of dexterous hands. At present, Aoyi Technology is continuously making efforts in product innovation. The new generation of dexterous hand ROH-AP001 will have sensory abilities such as touch and pressure, and is expected to be officially launched on the market in the near future.

In the field of neuroscience, Aoyi Technology has developed a medical grade neural interaction software and hardware integration infrastructure platform based on its self-developed brain/muscle machine interface technology, and has currently obtained over 80 patents. It includes the Brain Computer Interface OB series and the Intelligent Bionic Hand OHand ™ Multiple products including series, neural rehabilitation exoskeleton ORF series, etc. Among them, OHand ™ Since its launch in 2020, the intelligent bionic hand has quickly seized the market share of imported manufacturers with its ultimate technological performance and ultra-high cost-effectiveness. Meanwhile, in 2023, OHand ™ The bionic hand has successively obtained FDA/CE certification and obtained the PDAC commercial insurance payment code in the United States last year. It has taken the lead in overseas commercialization to multiple countries and regions around the world, such as the United States, the Middle East, Russia, Ukraine, and India. Aoyi Technology's bionic hand has become a business card for China's intelligent manufacturing.

Aoyi Technology has completed two rounds of financing in a short period of time, which is an important milestone in the company's development process. Standing at a new starting point, Aoyi Technology will uphold its original intention, be supported by capital strength, driven by technological innovation, and guided by market demand, constantly explore and strive to reach new heights.

Ni Hualiang, founder of Aoyi Technology, expressed gratitude to the trust and continuous support of new and old shareholders. The rapid completion of two rounds of financing in just a few months is not only a recognition of the company by shareholders, but also a reflection of the company's strong growth strength. After the completion of this round of financing, the Aoyi team will work closely with industry partners with a more open attitude to jointly promote the industrialization process of the neuroscience and robotics industries, and strive to become a leading global technology enterprise.